IL301897A - PROCESSES OF PREPARING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDROSquire Patton Boggs (US) LLP - L.A.1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE - Google Patents

PROCESSES OF PREPARING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDROSquire Patton Boggs (US) LLP - L.A.1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE

Info

Publication number
IL301897A
IL301897A IL301897A IL30189723A IL301897A IL 301897 A IL301897 A IL 301897A IL 301897 A IL301897 A IL 301897A IL 30189723 A IL30189723 A IL 30189723A IL 301897 A IL301897 A IL 301897A
Authority
IL
Israel
Prior art keywords
compound
organic solvent
pct
suitable organic
tetrahydrofuran
Prior art date
Application number
IL301897A
Other languages
Hebrew (he)
Inventor
Jiping Fu
Yan Lou
Yigang He
Yuetao Shi
Peng Zhou
Xingxing Li
Original Assignee
Nikang Therapeutics Inc
Jiping Fu
Yan Lou
Yigang He
Yuetao Shi
Peng Zhou
Xingxing Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikang Therapeutics Inc, Jiping Fu, Yan Lou, Yigang He, Yuetao Shi, Peng Zhou, Xingxing Li filed Critical Nikang Therapeutics Inc
Publication of IL301897A publication Critical patent/IL301897A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C07C29/38—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/58—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by elimination of halogen, e.g. by hydrogenolysis, splitting-off
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
    • C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/48—Halogenated derivatives
    • C07C35/52—Alcohols with a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/40—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with ozone; by ozonolysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C07C49/737—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

WO 2022/086822 PCT/US2021/055295 PROCESSES OF PREPARING 3-FLUORO-5-(((lS,2AR)-l,3,3,4,4-PENTAFLUORO-2A- HYDROXY-2,2A,3,4-TETRAHYDRO-lH-CYCLOPENTA[CD]INDEN-7-YL)OXY)- BENZONITRILE Cross-Reference to Related Applications This application is a PCT International Application claiming the benefit of PCT International Application No. PCT/CN2020/121745, filed on October 19, 2021, which is incorporated by reference herein in its entirety, Field of the disclosure Disclosed herein are processes for preparing 3-fluoro-5-(((lS,2aR)-l,3,3,4,4-pentafluoro- 2a-hydroxy-2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-7-yl)oxy )benzonitrile (hereinafter Compound (I)) having the structure: (1) or a pharmaceutically acceptable salt thereof.
Background Compound (I) is a hypoxia inducible factor -2a (HIF-2a) inhibitor and is being developed for treating diseases mediated by aberrant activity of HIF-2a including cancer, such as renal cancer, glioblastoma, neuroblastoma, pheochromocytomas and paragangliomas, somatostatinomas, hemangioblastomas, gastrointestinal stromal tumors (GIST), pituitary tumors, leiomyomas, leiomyosarcomas, polycythaemia, and retinal tumors and non-cancer diseases such as pulmonary artery hypertension (PAH), reflux esophagitis, hepatic steatosis, NASH, inflammatory disease such as inflammatory bowel disease, autoimmune disease such as Graft- versus-Host-Disease, and iron overload.Synthesis of Compound (I) is disclosed in Example 5 of PCT Application Publication No. WO 2020/214853, filed on April 16, 2020. There is a need for alternative processes that allow for WO 2022/086822 PCT/US2021/055295 large scale synthesis of Compound (I) in a cost-effective manner. The processes disclosed herein fullfill this and related needs. Summary Provided herein is a process that make it feasible to produce Compound (I) in high purity, including enantiomeric purity , and yield in a cost-effective manner and that is suitable for use on a commercial scale. Also, provided are processes for preparing certain intermediates used in such process.In one aspect, provided is a process of preparing compound (11) HO (ID compnsing reducing the keto moiety of compound (10): O (10) with:(a) sodium borohydride in an organic solvent selected from a group consisting of (i) an alcohol containing acetic acid or trifluoroacetic acid, (ii) a cyclic ether, and (iii) a mixture of a cyclic ether and an alcohol wherein the cyclic ether of (ii) and the mixture of a cyclic ether and an alcohol of (iii) optionally contain acetic acid or trifluoroacetic acid; or(b) lithium borohydride in a suitable organic solvent optionally containing acetic acid or trifluoroacetic acid.
WO 2022/086822 PCT/US2021/055295 In a first embodiment of a second aspect, provided is a process of preparing Compound (I): FF (I) comprising: (1) preparing compound (11): FHO (H) comprising reducing the keto moiety of compound (10): F (10) with: (a) sodium borohydride in an organic solvent selected from a group consisting of (i) an alcohol containing acetic acid or trifluoroacetic acid, (ii) a cyclic ether, and (iii) a mixture of a cyclic ether and an alcohol wherein the cyclic ether of (ii) and the mixture of a cyclic ether and an alcohol of (iii) optionally contain acetic acid or trifluoroacetic acid; or(b) lithium borohydride in a suitable organic solvent optionally containing acetic acid or tri fluoroacetic acid; and WO 2022/086822 PCT/US2021/055295 (ii) converting compound (11): HO (11) to Compound (I): (I) by reacting compound (11) with a deoxyfluorinating agent in the presence of an organic base in a suitable organic solvent.
In a second embodiment of a second aspect, the process of the first aspect, furthercomprises converting compound (11): HO (11) to Compound (I): (I) WO 2022/086822 PCT/US2021/055295 by reacting compound (11) with a deoxyfluorinating agent in the presence of an organic base in a suitable organic solvent.
In a third aspect, provided is a process of preparing compound (10): comprising reacting compound (9):(10) (9) with 3-fluoro-5-hydroxy benzonitrile in the presence of a base in a suitable organic solvent other than dimethylformamide.
In a fourth aspect, the processes of the first aspect and each embodiment of the secondaspect, further comprise preparing compound (10): (10) by reacting compound (9): (9) WO 2022/086822 PCT/US2021/055295 with 3-fluoro-5-hydroxybenzonitrile in the presence of a base in a suitable organic solvent.
In a fifth aspect, provided is a process for preparing compound (9): (9) comprising carrying out oxidative cleavage of the vinylidene moiety of compound (8): (8) with (i) sodium periodate in the presence of ruthenium chloride in aqueous acetonitrile, (ii) Oxone® in the presence of ruthenium chloride in a suitable organic solvent, or (iii) Ozone® in asuitable organic solvent.In a sixth aspect, the processes of the third and fourth aspects, further comprise preparingcompound (9): (9) by carrying out oxidative cleavage of the vinylidene moiety of compound (8): (8) WO 2022/086822 PCT/US2021/055295 with a suitable oxidizing agent in a suitable organic or aqueous organic solvent.
In a seventh aspect, provided is a process for preparing compound (8): comprising performing intramolecular cyclization between the alkene and bromo groups incompound (7): (7) by treating compound (7) with a palladium catalyst in the presence of a base in a suitable organic solvent other than dimethylformamide.
In an eighth aspect, the processes of the fifth and sixth aspects, further comprise preparing compound (8): (8) by performing intramolecular cyclization between the alkene and bromo groups in compound (7): (7) WO 2022/086822 PCT/US2021/055295 with a palladium catalyst in the presence of a base in a suitable organic solvent.
In a ninth aspect, provided is a process for preparing compound (7): (7) comprising brominating compound (6): (6) with l,2-dibromo-l,l,2,2-tetrafluoroethane in the presence of a deprotonating agent in a suitable organic solvent.
In a tenth aspect, the processes of the seventh and eighth aspects, further comprisepreparing compound (7): by treating compound (6): WO 2022/086822 PCT/US2021/055295 with a brominating agent in the presence of a deprotonating agent in a suitable organic solvent.
In an eleventh aspect, the processes of the ninth and tenth aspects, further comprise preparing compound (6): (6)by treating compound (5): with 4,4,5,5-tetramethyl-2-(prop-2-en-l-yl)-l,3,2-dioxaborolane in the presence of (S)-2-((3-(tert- butyl)-2-hydroxybenzyl)amino)-N,N,3-trimethylbutanamide and a base in a suitable organic solvent.
In a twelfth aspect, the process of eleventh aspect, further comprises preparing compound (5): (5) by treating compound (4): (4) WO 2022/086822 PCT/US2021/055295 with an organohthium reagent in a suitable organic solvent.
In a thirteenth aspect, the process of twelfth aspect, further comprises preparing compound (4): F (4) by treating compound (3): F(3) with a fluorinating agent in a suitable organic solvent.
In a fourteenth aspect, the process of thirteenth aspect, further comprises preparing compound (3): F(3) by treating compound (2): F (2) WO 2022/086822 PCT/US2021/055295 with an oxidizing agent in a suitable organic solvent.
In a fifteenth aspect, the process of fourteenth aspect, further comprises preparing compound (2): F. F•^o^X^ohO J^BrMF (2) by treating compound (1): (1) with ethyl 2-bromo-2,2-difluoroacetate in the presence of zinc metal, trimethylsilyl chloride, and 1,2-dibromoethane in a suitable organic solvent.
Detailed Description Definitions:Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:As used herein, the term "reacting" or "treating" when describing a certain process is used as known in the art and generally refers to the bringing together of chemical reagents in such a manner so as to allow their interaction at the molecular level to achieve a chemical or physical transformation. The reacting steps of the processes described herein can be conducted for a time and under conditions suitable for preparing the identified product."Suitable organic solvent" refers to an organic solvent which, under the reaction conditions of the processes disclosed herein, does not enter into any appreciable reaction with either the reactants, intermediates an/or the products at the temperatures at which the reactions are carried out. A given reaction disclosed herein can be carried out in one organic solvent or a mixture of WO 2022/086822 PCT/US2021/055295 two or more organic solvents. Examples of suitable organic solvents that can be used in the reactions described herein include: halogenated solvents such as carbon tetrachloride, chloroform, dichloromethane, and the like; ethers such as tetrahydrofuran, 2-methyltetrahydrofuran, 1,3-dioxane, 1,4-dioxane, diethyl ether, methyl t-butyl ether, and the like; alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, n-butyl alcohol, tert-butyl alcohol, 1-, 2-, or 3-pentanol, neo-pentyl alcohol, and the like; hydrocarbons (including, for example, alkane solvent) such as benzene, toluene, xylene, cyclohexane, pentane, hexane, heptane, and the like. Additional organic solvents that can be used in the reactions described herein include polar organic solvents including, but not limited to, acetonitrile, dimethylformamide, ethyl acetate, alcohols, and the like. When polar organic solvents (e.g., alcohols, acetonitrile, DMF) contain water they are referred to herein as aqueous organic solvent. Depending on the reaction step, solvents that are suitable for the particular reaction step can be readily selected by a person skilled in the art.For example, in the preparation of compound (2), besides, THF, the reaction was also carried out in MTBE, 2-methylTHF, or toluene solvent. In the preparation of compound (3), the reaction was also carried out in THFsolvent. In the preparation of compound (4), the reaction was also carried out in CHCl3 solvent. In the preparation of compound (5), the reaction was also carried out in 2-methyl THF, n-heptane, or MTBE solvent. In the preparation of compound (8), the reaction was also carried out in DMF, 1,4-dioxane, THF, 2-methyl THF, toluene, oracetonitrile solvent. In the preparation of compound (9), the reaction was also carried out in a mixture of DCM/ACN/water. In the preparation of compound (10), the reaction was also earned out in DMF, ACN, 2-methyl THF, or toluene solvent. In the preparation of compound (11), the reaction was also carried out in THF, CH3OH, TFA/THF, or HOAc/THF solvent. In the preparation of compound (I), the reaction was also carried out in DCM, CH3CN, 2-methyl THF, ethyl acetate, DMF, MTBE or toluene solvent.In addition, the reactions were carried out at various temperatures. Reaction temperatures that were used in the preparation of compound (2) included 20 °C, 40 °C, 60 °C, and refluxing. Reaction temperatures that were used in the preparation of compound (3) included 0 - 15 °C and 15-25 °C. Reaction temperatures that were used in the preparation of compound (4) included - 10 °C, 10 - 20 °C, 20 - 30 °C, and 30 - 40 °C. Reaction temperatures that were used in the preparation of compound (5) included -30 to -40 °C, -40 to -50 °C, -50 to -60 °C, and -60 to -°C. Reaction temperatures that were used in the preparation of compound (6) included 35 °C, °C, and 60 °C. Reaction temperatures that were used in the preparation of compound (7) WO 2022/086822 PCT/US2021/055295 included -100 to -80 °C, -80 to -60 °C, and -60 to -40 °C. Reaction temperatures that were used in the preparation of compound (8) included 60 °C, 70 °C and refluxing. Reaction temperatures that were used in the preparation of compound (10) included 20 to 30 °C, and 40 °C. Reaction temperatures that were used in the preparation of compound (11) included 10 to 20 °C and -5 to °C. And Reaction temperatures that were used in the preparation of compound (I) included 20 to °C and -5 to 5 °C.Additionally, bases that were used in the preparation of compound (8) included NaOAc, KO Ac, and K2CO3;brominating reagents that were used in the preparation of compound (7) included CBr4 and CF2BrCF2Br;catalysts that were used in the preparation of compound (8) included Pd(dppf)C12, Pd2(dba)3/XPhos, Pd(OAc)2/PPh3, and Pd(PPh3)C12,fluorinating reagents that were used in the preparation of compound (4) included DAST, 4-tert-butyl-2,6-d1methylphenylsulfur trifluoride, and HF/SF4;fluorinating reagents that were used in the preparation of compound (I) included DAST, PyFluor, AlkylFluor and SulfoxFluor;oxidizing agents that were used in the oxidation of compound (2) to (3) included 2-iodoxybenzoic acid (IBX), RuCl3/NaBrO3; TEMPO/NaClO, Mn02, and TPAP/NMOoxidizing agents that were used in the oxidation of compound (8) to (9) included RuC13/NaIO4, RuCl3/Oxonc® and 03; andreducing agents that were used in the reduction of compound (10) to (11) included LiBHand NaBH4.The reactions of the processes described herein can be carried out in air or under an inert atmosphere. Typically, reactions containing reagents or products that are substantially reactive with air can be carried out using air-sensitive synthetic techniques that are well known to the skilled artisan.The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry, or mass spectrometry; or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography. The compounds obtained by the reactions can be purified by any suitable method known in the art. For example, chromatography (medium pressure) on a suitable adsorbent (e.g., silica gel, alumina and the like), HPLC, or preparative thin WO 2022/086822 PCT/US2021/055295 layer chromatography; distillation; sublimation, trituration, or recry stallization. The purity of the compounds, in general, are determined by physical methods such as measuring the melting point (in case of a solid), obtaining an NMR spectrum, or performing a HPLC separation."Cyclic ether" refers to tetrahydrofuran, 2-methyltetrahydrofuran, or 1,4-dioxane. "Alcohol" refers to an aliphatic hydrocarbon compound that carries a hydroxy group.Representative examples include, but are not limited to, methanol, ethanol, propanol, butanol, and the like."About" as used herein means ± 10%, preferably ± 5% of listed value. For example, a reaction carried out at about 10 °C includes 9 °C, 11 °C, and all temperatures contained in between 9 °C and 11 °C.Embodiments:1. In embodiment 1, provided is a process of preparing compound (11)NC pA CF| ',OHHO(IDcomprising reducing the keto moiety of compound (10): (10)with:(a) sodium borohydride in an organic solvent selected from a group consisting of (i) an alcohol containing acetic acid or trifluoroacetic acid, (ii) a cyclic ether, and (iii) a mixture of a cyclic ether and an alcohol; wherein the cyclic ether of (ii) and the mixture of a cyclic ether and an alcohol of (iii) optionally contain acetic acid or trifluoroacetic acid; or(b) lithium borohydride in a suitable organic solvent optionally containing acetic acid or trifluoroacetic acid.2. In embodiment 2, provided is a process of preparing Compound (I) as described in the first and second embodiments of the second aspect of the Summary.2a. In embodiment 2a, provided is a process of preparing Compound (I) as described in the first embodiment of the second aspect of the Summary .
WO 2022/086822 PCT/US2021/055295 2b. In embodiment 2b, provided is a process of preparing Compound (I) as described in the second embodiment of the second aspect of the Summary'.3. In embodiment 3, the process of embodiment 2, 2a or 2b is wherein the deoxyfluorinating agent is diethylaminosulfur trifluoride, Phenofluor™, N-tosyl-4-chlorobenzene- sulfonimidoyl fluoride, pyridine-2-sulfonyl fluoride, or AlkylFluor.4. In embodiment 4, the process of embodiment 2, 2a (in step (ii)), 2b, or 3 is wherein the organic solvent is halogenated hydrocarbon, cyclic ethers, ethers, aromatic hydrocarbon, or a polar solvent. Preferably, the organic solvent is dichloromethane, acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, ethylacetate, dimethylformamide, methyl tert-buty lether, or toluene.5. In embodiment 5, the process of embodiment 2, 2a, or 2b is wherein the deoxyfluorinating agent is pyridine-2-sulfonyl fluoride and the base is 1,8-diazabicyclo- [5.4.0]undec-7-ene or 7-methyl-l,5,7-triaza-bicyclo[4.4.0]dec-l-ene.6. In embodiment 6, the process of embodiment 1,2a, 2b or 2b is wherein the reduction of the keto group of compound (10) is earned out with sodium borohydride in tetrahydrofuran, 2-methyltetrahydrofuran, a mixture of tetrahydrofuran or 2- methyltetrahydrofuran and methanol, tetrahydrofuran containing acetic acid or trifluoroacetic acid, 2-methyltetrahydrofuran containing acetic acid or trifluoroacetic acid, or methanol containing acetic acid or trifluoroacetic acid.7. In embodiment 7, the process of embodiment 6 is wherein the organic solvent is a mixture of tetrahydrofuran and methanol and the reaction is carried out at about -5 °C to about 30°C.8. In embodiment 8, the process of embodiment 6 is wherein the organic solvent is a mixture of tetrahydrofuran and methanol and the reaction is carried out at about -5 °C to about °C.9. In embodiment 9, the process of embodiment 5 is wherein the molar ratio of 1,8- diazabicyclo[5.4.0]-undec-7-ene to compound (11) is at least about 2 to about 1 and the organic solvent is tetrahydrofuran.10. In embodiment 10, the process of embodiment 5 or 9 is wherein the reaction is carried out at 20 °C to about 30 °C WO 2022/086822 PCT/US2021/055295 11. In embodiment 11, provided is process of preparing compound (10): comprising reacting compound (9): F ؟؛<؛LjOHo(9)with 3-fluoro-5-hydroxybenzonitrile in the presence of a base in a suitable organic solvent other than dimethylformamide.12. In embodiment 12, the process of any one of embodiments 1 to 10 furthercomprises preparing compound (10): by reacting compound (9): (9)with 3-fluoro-5-hydroxy benzonitrile in the presence of a base in a suitable organic solvent.13. In embodiment 13, the process of embodiment 11 or 12 is wherein the base is an inorganic base.14. In embodiment 14, the process of embodiment 13 is wherein the inorganic base is cesium carbonate or potassium carbonate.15. In embodiment 15, the process of any one of embodiments 11 to 14 is wherein the organic solvent is tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide, acetonitrile, or toluene.
WO 2022/086822 PCT/US2021/055295 16. In embodiment 16, the process of embodiment 15 is wherein the organic solvent is tetrahydrofuran.17. In embodiment 17, the process of any one of embodiments 11 to 16 is wherein the reaction is carried out at about 20 °C to about 40 °C.18. In embodiment 17, the process of any one of embodiments 11 to 17 further comprises crystallizing compound (10) from a mixture of an ether and an alkane solvent.19. In embodiment 19, the process of embodiment 18 is wherein compound (10) is crystallized from a mixture of methyl tert-butyl ether and n-heptane.20. In embodiment 20, provided is a process for preparing compound (9): o(9)comprising carrying out oxidative cleavage of the vinylidene moiety of compound (8): (8)with (i) sodium periodate in the presence of ruthenium chloride in aqueous acetonitrile, (ii) Oxone® in the presence of ruthenium chloride in a suitable organic or aqueous organic solvent, or (iii) Ozone in a suitable organic or aqueous organic solvent.21. In embodiment 21, the process of any one of embodiments 11 to 19 further comprises preparing compound (9): O(9) WO 2022/086822 PCT/US2021/055295 by carrying out oxidative cleavage of the vinylidene moiety of compound (8): (8) with a suitable oxidizing agent agent in a suitable organic or aqueous organic solvent.22. In embodiment 22, the process of embodiment 21 is wherein the oxidative cleavage of the vinylidene is carried out with (i) sodium periodate or Oxone® in the presence of ruthenium chloride or (ii) Ozone.23. In embodiment 23, the process of embodiment 21, is wherein the solvent is a mixture of di chloromethane, acetonitrile and water or the solvent is aqueous acetonitrile.24. In embodiment 24, the process of any one of embodiments 20 to 23 is wherein the oxidative cleavage of the vinylidene is carried out with sodium periodate in the presence of catalytic amount of ruthenium chloride in aqueous acetonitrile.24a. In embodiment 24a, the process of any one of embodiments 20 to 24 further comprises purification of compound (9) from a mixture of an ether and an alkane solvent.24b. In embodiment 24b, the process of embodiment 24a is wherein punfication of compound (9) is from a mixture of methyl tert-butyl ether and n-heptane.25. In embodiment 25, provided is a process for preparing compound (8): (8)comprising performing intramolecular cyclization between the alkene and bromo groups in compound (7): (7)by treating compound (7) with a palladium catalyst in the presence of a base in a suitable organic solvent other than dimethylformamide.
WO 2022/086822 PCT/US2021/055295 26. In embodiment 26, the process of any one of embodiments 20 to 24 further comprises preparing compound (8): (8)by performing intramolecular cyclization between the alkene and bromo groups in compound (7): FF pO^F F I / OHBr (7)with a palladium catalyst in the presence of a base in a suitable organic solvent.27. In embodiment 27, the process of embodiment 25 or 26 is wherein the palladium catalyst is Pd(PPh3)4, Pd(dppf)C12, Pd(PPh3)2C12, Pd(PPh3)2(OAc)2, Pd2(dba)3/XPhos, or Pd(l ,2- bis(d1phenylphosphino)ethane)(OAc)2, and the organic solvent is acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, 1,4-di oxane, or dimethylformamide.28. In embodiment 28, the process of embodiment 27 is wherein the base is sodium acetate, potassium acetate, sodium carbonate, potassium carbonate or cesium carbonate.29. In embodiment 29, the process of any one of embodiments 25, 26, or 28 is wherein the palladium catalyst is Pd(PPh3)2C12, the base is potassium acetate, and the solvent is acetonitrile.30. In embodiment 30, the process of embodimen 29 is wherein the reaction is carried out between about 60 °C to about 80 °C31. In embodiment 31, provided is a process for preparing compound (7): (7)comprising brominating compound (6): WO 2022/086822 PCT/US2021/055295 f ؟XxSfF 7 OH (6)with l,2-dibromo-l,l,2,2-tetrafluoroethane in the presence of a deprotonating agent in a suitable organic solvent.32. In embodiment 32, the process of any one of embodiments 25 to 30 furthercomprises preparing compound (7): (6)with a brominating agent in the presence of a deprotonating agent in a suitable organic solvent.33. In embodiment 33, the process of embodiment 32 is wherein the brominating agent is carbon tetrabromide or l,2-dibromo-l,l,2,2-tetrafluoroethane.33a. In embodiment 33a, the process of embodiment 32 is wherein the brominating agent is bromotrichloromethane, l,2-dibromo-I,l,2,2-tetrachloroethane, l,2-dibromo-l,L2,2- tetrafluoroethane, carbon tetrabromide, JV-bromosuccinimide, N-bromophthalimide, /V-bromosaccharin, 7V-bromoacetamide, l,3-dibromo-5,5־dimethylhydantoin, dibromoisocyanuric acid, monosodium bromoisocyanurate, bromodimethylsulfonium bromide. 5,5-dibromomeldrum's acid, 2,4,4,6-tetrabromo-2,5-cyclohexadienone, bis(2,4,6-trimethylpyridine)-bromonium hexafluorophosphate; and bromine and its equivalents, such as bromine - 1,4-dioxane complex, tetrabutylammonium tribromide, trimethyiphenyiammonium tnbromide, benzyltrimethyl ammonium tribromide, and I-butyl-3-methylimidazolium tribromide.
WO 2022/086822 PCT/US2021/055295 34. In embodiment 34, the process of embodiment 31 or 32 is wherein the brominating agent is l,2-dibromo-l,l,2,2-tetrafluoroethane, the deprotonating agent is lithium diisopropylamide and the solvent is tetrahydrofuran.35. In embodiment 35, the process of embodiment 34 is wherein the reaction is earned at out at about -100 °C to about -20 °C.36. In embodiment 36, the process of any one of embodiments 31 to 35 further comprises preparing compound (6): by treating compound (5): (5)with 4,4,5,5-tetramethyl-2-(prop-2-en-l-yl)-l,3,2-dioxaborolane in the presence of (S)-2-((3-(tert- butyl)-2-hydroxybenzyl)amino)-N,N,3-trimethylbutanamide and a base in a suitable organic solvent.37. In embodiment 37, the process of embodiment 36 is wherein the base is sodium tert-butoxide and the organic solvent is a mixture of methanol and toluene.38. In embodiment 38, the process of claim 36 or 37 further comprises preparing compound (5): by treating compound (4): WO 2022/086822 PCT/US2021/055295 with an organolithium reagent in a suitable organic solvent.39. In embodiment 39, the process of claim 38 is wherein the organolithium reagent is n-butyllithium and the organic solvent is tetrahydrofuran, 2-methyltetrahydrofuran, n-heptane and methyl tert-butylether.40. In embodiment 40, the process of embodiment 38 or 39 is wherein the solvent is tetrahydrofuran.41. In embodiment 41, the process of any one of embodiments 38 to 40 further comprises preparing compound (4): F(4)by treating compound (3): (3) with a fluorinating agent in a suitable organic solvent.42. In embodiment 42, the process of claim 41 is wherein the fluorinating agent is diethylaminosulfur trifluoride, 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride, or sulfur tetrafluoride and hydrofluoric acid.43. In embodiment 43, the process of embodiment 42 is wherein the fluorinating agent is sulfur tetrafluoride and hydrofluoric acid and the solvent is dichloromethane.44. In embodiment 44, the process of any one of embodiments 41 to 43 further comprises preparing compound (3): F(3) WO 2022/086822 PCT/US2021/055295 by treating compound (2): F (2) with an oxidizing agent in a suitable organic solvent.45. In embodiment 45, the process of embodiment 44 is wherein the oxidizing agent is dimethyl sulfoxide/oxalyl chloride, 2-iodoxybenzoic acid, RuC13/NaBrO3, Mn02, NaBrO3/NaHSO3. or TPAP/NMO.46. In embodiment 46, the process of embodiment 45 is wherein the oxidizing agent is is TPAP/NMO and reaction is carried in dichloromethane, acetonitrile or tetrahydrofuran, preferably dichloromethane.47. In embodiment 47, the process of any one of embodiments 44 to 46 further comprises preparing compound (2): (2)by treating compound (1): F(1)with ethyl 2-bromo-2,2-difluoroacetate in the presence of zinc metal, trimethylsilyl chloride, and1,2-dibromoethane in a suitable organic solvent.48. In embodiment 48, the process of embodiment 47 is wherein the organic solvent is tetrahydrofuran or 2-methyl tetrahydrofuran.EXAMPLESAbbreviations:ACN: acetonitrileAcOH or HO Ac: acetic acid WO 2022/086822 PCT/US2021/055295 AlkylFluor: CAS Registry No. 2043361-32-4C52CO3: cesium carbonateDAST: diethylaminosulfur trifluorideDCM: dichloromethaneHF: hydrofluoric acidHC1: hydrochloric acidKO Ac: potassium acetateLDA: Lithium diisopropylamideMTBE: methyl tert-buty l etherNMO: N-Methy!morpholine N-oxideMeOH: methanolNaBH4: sodium borohydrideNalO4: sodium perodiaten-BuLi: n-butyllithiumPd(PPh3)2(OAc)2: bis(acetato)bis(triphenylphosphine)palladium(II)Pd(PPh3)2C12: bis(triphenylphosphine)palladium(II) dichloridePd2(dba)3: tris(dibenzylideneacetone)dipalladium(0)PyFluor: 2-pyridinesulfonyl FluorideRuC13e3H2O: ruthenium (III) chloride hydrateSF4: sulfur tetrafluorideSulfoxFluor: [methyl(oxo){l-[6-(trifluoromethyl)-3-pyridyl]ethyl}-X6-sulfanyhdene]cyanamideTEMPO: (2,2,6.6-Tetramethylpiperidin-l-yl)oxyl or (2,2,6,6-tetramethylpiperidin-l-yl)oxidanyl TFA: trifluoroacetic acidTHF: tetrahydronfuranTPAP: tetrapropylammonium perruthenatet-BuONa: sodium tert-butoxideXPhos: 2-dicyclohexylphosphino-2',46,׳'-triisopropylbiphenyl WO 2022/086822 PCT/US2021/055295 Example 1 Synthesis of 2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l-one Step 1:ethyl 3-(2-bromo-4-fluorophenyl) -2,2-difluoro-3-hydroxypropanoate To a mixture of zinc (211.36 g, 3.23 mol, 1.31 eq.) in THF (1.50 L) was added 1 2-dibromoethane (13.88 g, 73.89 mmol, 0.030 eq.) and TMSCI (53.52 g, 492.59 mmol, 0.20 eq.) in one portion. The mixture was stirred at 25 °C for 0.5 h, then a solution of 2-bromo-4- fluoro-benzaldehyde (500 g, 2.46 mol, 1.00 eq.) and ethyl 2-bromo-2,2-difluoro-acetate (549.93 g, 2.71 mol, 1.10 eq.) in THF (1.50 L) was added to the mixture dropwise over 1 h under refluxing, and the reaction mixture was stirred continually under refluxing for 1 h. The reaction mixture was cooled, then filtered, and the cake was washed with ethyl acetate. The filtrate was quenched with 1.0 M aqueous HC1 (800 mL), then adjusted to pH = 5-6 and the mixture was extracted with ethyl acetate. The combined organic phase was washed with 10% brine, dried w1thNa2SO4, concentrated in vacuum to give the title compound (857.0 g,, 88.8% assay purity, 94.5% assay yield) as a yellow oil, which was used for next step without further purification. Step 2:ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-oxopropanoate F F A mixture of NMO (297.86 g, 2.54 mol, 1.40 eq.), TPAP (15.96 g, 45.41 mmol, 0.025 eq.) and 4A MS (94.0 g) in DCM (1000 mL) was degassed and purged with N2 and a solution of ethyl 3-(2-bromo-4-fluorophenyl)- 2,2-difluoro-3-hydroxypropanoate (669.00 g, 1.82 mol, 88.8% assay, 1.00 eq.) in DCM (1000 mL) was added dropwise at 0-5 °C over 1.5 h. The resulting mixture was further stirred at 25 °C for 2 h under N2 atmosphere, then was filtered through silica gel pad and WO 2022/086822 PCT/US2021/055295 the pad cake was washed with MTBE. The combined filtrate was washed with 1.0 M aqueous HC1 The combined aqueous phase was extracted with MTBE. The combined MTBE organic phase was washed with H2O, filtered through a silica gel pad and the pad cake was washed with MTBE. The combined filtrate was concentrated to give the title compound (561.0 g, 95.1% yield) as a yellow oil, which was used for next step without further purification.Alternative Method:To a stirred mixture of ethyl 3-(2-bromo-4-fluorophenyl)- 2,2-difluoro-3-hydroxy- propanoate (285.9 g, after assay adjustment, 0.874 mol, 1.00 eq.) in acetonitrile (900 mL) and water (900 mL) were added NaH2PO4 (63.0 g, 0.525 mol, 0.60 eq.) and RuCl (1.81 g, 8.7mmol, 0.010 eq.) sequentially at 20-30 °C. NaBrO3 (158.27 g, 1.049 mol, 1.20 eq.) was then added in portions at 20-30°C. After further stirring at 20-30°C for 2 h, the reaction mixture was diluted with EtOAc, followed by w ashing with water, aqueous Na2SO3, water and then brine. The organic layer was concentrated to obtain the title compound (272.8 g, 95.2% purity, 91.4% yield) as a yellow oil, which was used for next step without further purification. Step 3:ethyl 3-(2-bromo-4-fluorophenyl)-2,2,3,3-tetrafluoropropanoate F F To an autoclave was charged ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3- oxopropanoate (550.00 g, 1.69 mol, 1.00 eq.) and DCM (55.5 mL). The mixture w as cooled to -°C and HF (33.85 g, 1.69 mol, 1.00 eq.) was charged, followed by SF4 (202.00 g, 1.87 mol, 1.eq.). The reaction mixture was warmed to room temperature and stirred at this temperature for h. The reaction mixture was quenched by added slowly into saturated aqueous Na2CO3 (2.5 L) and then extracted with petroleum ether. The combined organic layer was w ashed with 10% brine, dried 0verNa2S04, filtered and concentrated. The residue was further purified by vacuum distillation to afford the title compound (474.0 g, 81.1% yield) as yellow oil. Step 4:2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l -one WO 2022/086822 PCT/US2021/055295 A stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2,3,3-tetrafluoropropanoate (100.0. g, 288.11 mol, 1.00 eq.) inTHF (1.0 L) was cooled to -65 °C, andn-BuLi (2.5 M, 138.mL, 345.0 mol, 1.20 eq.) was added dropwise at -60 to -70 °C over 1 h under nitrogen atmosphere. The resulting mixture was stirred further at -65 °C for 1 h, then was quenched with saturated aqueous NH4Cl at -30 to -40 °C, followed by dilution with ethyl acetate and H2O. After phase separation, the aqueous phase was extracted with ethyl acetate and the combined organic layer was washed with 10% brine, dried 0verNa2S04, filtered and concentrated to give a residue. The residue was purified by vacuum distillation, and the distillate was triturated with petroleum ether at low temperature to give the title compound (41.0 g, 64.1% yield) as a white solid.
Example 2 Synthesis of (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-l-one Step 1:(R)-l-allyl-2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l-ol To a dry 3-neck flask were added 2-allyl-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (94.57 g, 562.78 mmol, 1.21 eq.), (S)-2-((3-(tert-butyl)-2-hydroxybenzyl)amino)-N,N,3-trimethyl- butanamide (36.51 g, 119 14 mmol, 0.26 eq ), t-BuONa (4.33 g, 45.06 mmol, 0.097 eq ), toluene (900 mL) and MeOH (28.8 g, 898.88 mmol, 1.94 eq.). The mixture was stirred at 20 °C under nitrogen atmosphere until a clear solution formed. The reaction mixture was heated to 60 °C, and a solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l-one (103.09 g, 464.14 mmol, 1.00 eq.) in toluene (100 mL) was added slowly over 2 h at 60 °C. The resulting mixture was stirred continually for 16 h at 60 °C, then cooled to room temperature, quenched with water, and extracted with MTBE. The organic layer was cooled to 0 °C andwashed with 1.0 M aqueous HC1, WO 2022/086822 PCT/US2021/055295 0.5 M aqueous NaOH, water and 10% brine. The organic layer was concentrated to give the title compound (146.71g, 73.5% assay purity, 87.9% assay yield, 90.7% e.e.). Step 2:(R)-l-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l-ol To a dry 3-neck flask were added THF (500 mL) and LDA (356.82g, 25%, 832.76 mmol, 2.21 eq.) and then the solution was cooled to -50 °C under nitrogen atmosphere. A solution of (R)-l-allyl-2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l-ol (100.00 g, 378.50 mmol, 1.00 eq.) in THF (200 mL) was added slowly at -50 °C. The resulting mixture was stirred at -50 °C for Ih, then cooled to -80 °C to form solution A.To another dry 3-neck flask were added dibromotetrafluoroethane (196.66 g, 756.mmol, 2.00 eq.) and THF (100 mL), and the solution was cooled to -80 °C. Solution A was slowly added with stirring and while maintaining the reaction temperature at about -80 °C. The mixture was stirred at -80 °C for additional 30 min and then slowly quenched by slowly adding a solution of AcOH (75.00 g, 1248.96 mmol, 3.30 eq.) in THF (75 mL) at temperature below -60 °C. The mixture was warmed slowly to room temperature anddiluted with water. The mixture was extracted with MTBE, and the combined organic layer was washed with water and 10% brine. The organic layer was concentrated to give the title compound as a solution in THF (204.40g, 50.4% assay purity, 79.3% assay yield). Step 3:(R)-3,3,4,4,7-pentafluoro-l-methylene-l,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol Into a solution of (R)-l-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-lH-inden-l-ol (100.00 g, 291.47 mmol, 1.00 eq.) in acetonitnle (1.50 L) were added KOAc (86.50g, 881.mmol, 3.03 eq.) and Pd(PPh3)2Ch (10.30 g, 14.67 mmol, 0.050 eq.) under N2 atmosphere. The mixture was stirred for 4 h at 80 °C and then concentrated under vacuum to about 1/3 volume. The residue was diluted with MTBE and washed with water. The organic layer was diluted with WO 2022/086822 PCT/US2021/055295 n-heptane and passed through a silica gel pad (200 g). The pad was rinsed with MTBE/n-heptane=l/3 to wash out the product. The eluent was concentrated and exchange the solvent into acetonitnle to give the title compound as a solution in acetonitrile (120.15g, 51.7% assay purity, 81.3% assay yield, 90.6% e.e.). Step 4:(R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-l-one To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-l-methylene-l,2,3,4-tetrahydro-2aH- cyclopenta[cd]inden-2a-ol (80.00 g, 305.13 mmol, 1.00 eq.) in ACN (1200 mL) and H2O (32mL) was added RuC13*3H2O (4.00 g, 15.30 mmol, 0.050 eq.), followed by NaIO4 (456.87 g, 2.mol, 7.01 eq.) in portions while maintaining the reaction temperature at 10 to20 °C. After stirring further at 10 to 20 °C for 1 h, MTBE (800 mL) was added to the mixture and the mixture w as filtered through a Celite layer. The Celite solid cake was washed with MTBE. The organic layer was separated from the combined filtrate, and the aqueous layer was extracted with MTBE The combined organic layer was washed with 5% aqueous Na2SO3 and 10% aqueous Na2SO4. The organic layer w as concentrated, and the residue was dissolved in MTBE and n-heptane. The solution was filtered through a silica gel pad (200 g) and the pad solid cake was rinsed with MTBE/n-heptane=l/3. The combined eluent was concentrated to about 3V to precipitate out the product which was filtered and dried to give the title compound as a white solid (70.62 g, 88.4% assay purity', 77.5% assay yield, ~ 91.7% e.e.).
Example 3 Synthesis of 3-fluoro-5-(((lR,2aR)-3,3,4,4-tetrafluoro-l,2a-dihydroxy- 2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-7-yl)oxy )benzonitrileN HO WO 2022/086822 PCT/US2021/055295 Step 1:(R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-l-oxo-2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-7-yl)oxy )benzonitrile To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-lH- cyclopenta[cd]inden -1 -one (100 00 g, after assay adjustment, 378.57 mmol, 1.00 eq.) in THF (500 mL) were added 3-fluoro-5-hydroxybenzon1trile (57.10 g, 416.45 mmol, 1.10 eq.) and C82CO3 (74.01 g, 227.15 mmol, 0.60 eq.) at room temperature. The resulting mixture was stirred at 40 °C for 20 h. The mixture was cooled to room temperature and MTBE was added, followed by water. After layer separation, the aqueous layer was extracted with MTBE and the combined organic layer was washed with 5% aqueous Na2CO3 and then 10% brine. The organic layer was concentrated and the residue was recrystallized from MTBE/n-heptane = 3/20 to give the title compound as a yellow solid (145.78 g, 84.4% assay purity, 85.2% assay yield, 98.4% e.e.).
Step 2:3-fluoro-5-(((lR,2aR)-3,3,4,4-tetrafluoro-l,2a-dihydroxy- 2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-7-yl)oxy )benzonitrile To a stirred solution of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-l-oxo-2,2a,3,4- tetrahydro-1H- cyclopenta[cd]inden-7-yl)oxy)benzonitrile (50.00 g, after assay adjustment, 131.mmol, 1.00 eq.) in MeOH (53.0 mL, 1.31 mol, 10.00 eq.) and THF (500 mL) was added NaBH(1.84 g, 48.64 mmol, 0.37 eq.) in portions at -5 to 0 °C. The reaction mixture was stirred at -5 to °C for an additional hour, then quenched with 2.0 M aqueous HC1 (about 30.0 g) below 5 °C to pH = 5-7 and diluted with water. The mixture was extracted with MTBE, and the combined organic layer was washed with water and 10% brine. The organic layer is concentrated and the solvent was exchanged to THF to obtain a THF solution of the title compound (286.66 g, 16.6% assay purity, 94.7% assay yield, 97.7% e.e.). 1HNMR (400MHz, CDC13) 5 = 7.55 (d, 1H), 7.18 - WO 2022/086822 PCT/US2021/055295 7.16 (m, 2H), 7.13 (d, 1H), 7.08 (d, 1H), 5.89-5.84 (m, 1H), 3.06 (s, 1H), 2.83 -2.78 (m, 1H), 2.47 - 2.42 (m, 1H), 2.35 (d, 1H).

Claims (36)

1.WO 2022/086822 PCT/US2021/055295 What is Claimed: 1. A process of preparing compound (11) 5(ID comprising reducing the keto moiety of compound (10): (10) with:(a) sodium borohydride in an organic solvent selected from a group consisting of (i)an alcohol containing acetic acid or trifluoroacetic acid, (ii) a cyclic ether, and (iii) a mixture of a cyclic ether and an alcohol; wherein the cyclic ether of (ii) and the mixture of a cyclic ether and an alcohol of (iii) optionally contain acetic acid or trifluoroacetic acid; or(b) lithium borohydride in a suitable organic solvent optionally containing acetic acid or trifluoroacetic acid.
2. The process of claim 1, further comprising converting compound (11): HO (ID to Compound (I): -32- WO 2022/086822 PCT/US2021/055295 (1) by reacting compound (11) with a deoxyfluorinating agent in the presence of an organic base in a suitable organic solvent.
3. The process of claim 2, wherein the deoxy fluorinating agent is pyridine-2-sulfonyl fluoride and the base is l,8-diazabicyclo-[5.4.0]undec-7-ene or 7-methyl-1,5,7-triaza-bi cyclo- [4.4.0]dec-l-ene.
4. The process of claim 1 or 2, wherein the reduction of the keto group of compound (10) is carried out with sodium borohydride in tetrahydrofuran, 2-methyltetrahydrofuran, a mixture of tetrahydrofuran or 2-methyltetrahydrofuran and methanol, tetrahydrofuran containing acetic acid or trifluoroacetic acid, 2-methyltetrahydrofuran containing acetic acid or trifluoroacetic acid, or methanol containing acetic acid or trifluoroacetic acid.
5. The process of claim 4, wherein the organic solvent is a mixture of tetrahydrofuran and methanol and the reaction is carried out at about -5 °C to about 30 °C.
6. The process of claim 3, wherein the molar ratio of l,8-diazabicyclo[5.4.0]-undec-7- ene to compound (11) is at least about 2 to about 1 and the organic solvent is tetrahydrofuran.
7. A process of preparing compound (10): (10) comprising reacting compound (9): -33 - WO 2022/086822 PCT/US2021/055295 O (9) with 3-fluoro-5-hydroxybenzonitrile in the presence of a base in a suitable organic solvent other than dimethylformamide. 5
8.(10):The process of any one of claims 1 to 6, further comprising preparing compound O (10) by reacting compound (9): (9) with 3-fluoro-5-hydroxy benzonitrile in the presence of a base in a suitable organic solvent.
9. The process of claim 7 or 8, wherein the base is an inorganic base.
10. The process of claim 9, wherein the inorganic base is cesium carbonate orpotassium carbonate
11. The process of claim 7 to 10, wherein the organic solvent is tetrahydrofuran.
12. The process of any one of claims 7 to 11, further comprising crystallizingcompound (10) from a mixture of an ether and an alkane solvent. -34- WO 2022/086822 PCT/US2021/055295
13. The process of claim 12, wherein compound (10) is crystallized from a mixture of methyl tert-butyl ether and n-heptane.
14. A process for preparing compound (9): O 5 (9) comprising carrying out oxidative cleavage of the vinylidene moiety of compound (8): with (i) sodium periodate in the presence of ruthenium chloride in aqueous acetonitrile, (ii)Oxone® in the presence of ruthenium chloride in a suitable organic or aqueous organic solvent, or (iii) Ozone in a suitable organic or aqueous organic solvent.
15. The process of any one of claims 7 to 13, further comprising preparing compound (9): 15 (9) by carrying out oxidative cleavage of the vinylidene moiety of compound (8): -35 - WO 2022/086822 PCT/US2021/055295 with a suitable oxidizing agent in a suitable organic or aqueous organic solvent.
16. The process of claim 14 or 15, wherein the oxidative cleavage of the vinylidene is carried out with sodium periodate in the presence of catalytic amount of ruthenium chloride in aqueous acetonitrile.
17. A process for preparing compound (8): (8) 10 comprising performing intramolecular cyclization between the alkene and bromo groups in compound (7): FVF h I / OH Br (7) by treating compound (7) with a palladium catalyst in the presence of a base in a suitable organicsolvent other than dimethylformamide. -36- WO 2022/086822 PCT/US2021/055295
18. The process of any one of claims 14 to 16, further comprising preparing compound (8): (8) 5 by performing intramolecular cyclization between the alkene and bromo groups in compound (7): F bTC0” (7) with a palladium catalyst in the presence of a base in a suitable organic solvent.
19. The process of claim 17 or 18, wherein the palladium catalyst is Pd(PPh3)4,Pd(dppf)Cla, Pd(PPh3)2C12, Pd(PPh3)2(OAc)2, Pd2(dba)3/XPhos, or Pd(l,2-bis(diphenylphosphino)- ethane)(OAc)2, and the organic solvent is acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, 1,4-di oxane, or di methyl formamide,
20. The process of claim 19, wherein the palladium catalyst is Pd(PPh3)2C12, the base is potassium acetate, and the solvent is acetonitrile.
21. A process for preparing compound (7): (7) comprising brominating compound (6): -37- WO 2022/086822 PCT/US2021/055295 (6) with l,2-dibromo-l,l,2,2-tetrafluoroethane in the presence of a deprotonating agent in a suitable organic solvent. 5
22. The process of any one of claims 17 to 20, further comprising preparing compound(7): (7) by treating compound (6): with a brominating agent in the presence of a deprotonating agent in a suitable organic solvent.
23. The process of claim 21 or 22, wherein the deprotenating agent is lithiumdiisopropylamide.
24. The process of claim 21 or 22, wherein the brominating agent is 1,2-dibromo-1,1,2,2-tetralluoroethane, the deprotenating agent is lithium diisopropylamide and the solvent is tetrahydrofuran. -38- WO 2022/086822 PCT/US2021/055295
25. The process of any one of claims 21 to 24, further comprising preparing compound (6): (6) 5 by treating compound (5): (5)with 4,4,5,5-tetramethyl-2-(prop-2-en-l-yl)-l,3,2-dioxaborolane in the presence of (S)-2-((3-(tert- butyl)-2-hydroxybenzyl)amino)-N,N,3-trimethylbutanamide and a base in a suitable organicsolvent.
26. The process of claim 25, wherein the base is sodium tert-butoxide and the organic solvent is a mixture of methanol and toluene.
27. The process of claim 25 or 26, further comprising preparing compound (5): by treating compound (4): F(4) -39- WO 2022/086822 PCT/US2021/055295 with an organolithium reagent in a suitable organic solvent.
28. The process of claim 27, wherein the organolithium reagent is n-butyllithium and the organic solvent is tetrahydrofuran.
29. The process of claim 27 or 28, further comprising preparing compound (4): 5 F(4) by treating compound (3): F(3) 10 with a fluorinating agent in a suitable organic solvent.
30. The process of claim 29, wherein the fluorinating agent is diethylaminosulfur trifluoride, 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride, or sulfur tetrafluoride and hydrofluoric acid.
31. The process of claim 30, wherein the fluorinating agent is sulfur tetrafluoride and hydrofluoric acid and the solvent is di chloromethane.
32. The process of claim 29, 30, or 31, further comprising preparing compound (3): F(3) -40- WO 2022/086822 PCT/US2021/055295 by treating compound (2): F (2) with an oxidizing agent in a suitable organic solvent. 5
33. The process of claim 32, wherein the oxidizing agent is DMSO/oxalyl chloride,2-iodoxybenzoic acid, RuC13/NaBrO3, Mn02, NaBrO3/NaHSO3 or TPAP/NMO.
34. The process of claim 33, wherein the oxidizing agent is is TPAP/NMO and reaction is carried in dichloromethane.
35. The process of any one of claims 32 to 34, further comprising preparing compound(2): E F O Jx״Br MJF(2) by treating compound (1): F(1) with ethyl bromodifluoroacetate in the presence of zinc metal, trimethylsilyl chloride, and1,2-dibromoethane in a suitable organic solvent.
36. The process of claim 35, wherein the organic solvent is tetrahydrofuran. -41 -
IL301897A 2020-10-19 2021-10-15 PROCESSES OF PREPARING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDROSquire Patton Boggs (US) LLP - L.A.1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE IL301897A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/121745 WO2022082329A1 (en) 2020-10-19 2020-10-19 Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile
PCT/US2021/055295 WO2022086822A1 (en) 2020-10-19 2021-10-15 Processes of preparing 3-fluoro-5-(((1s,2ar)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile

Publications (1)

Publication Number Publication Date
IL301897A true IL301897A (en) 2023-06-01

Family

ID=78536649

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301897A IL301897A (en) 2020-10-19 2021-10-15 PROCESSES OF PREPARING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDROSquire Patton Boggs (US) LLP - L.A.1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE

Country Status (9)

Country Link
EP (1) EP4229033A1 (en)
JP (1) JP2023548666A (en)
KR (1) KR20230092936A (en)
CN (1) CN116507601A (en)
AU (1) AU2021364337A1 (en)
CA (1) CA3197932A1 (en)
IL (1) IL301897A (en)
TW (1) TW202233569A (en)
WO (2) WO2022082329A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022082337A1 (en) 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
WO2023060431A1 (en) * 2021-10-12 2023-04-20 Nikang Therapeutics, Inc. Processes of making 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile and polymorphs thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105530923B (en) * 2013-09-09 2019-07-23 佩洛通治疗公司 Aryl ether and application thereof
US10098878B2 (en) * 2014-10-10 2018-10-16 The Board Of Regents Of The University Of Texas System HIF-2α inhibitors for treating iron overload disorders
EP3267792A4 (en) * 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016168510A1 (en) * 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) * 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
WO2017053192A1 (en) * 2015-09-21 2017-03-30 The Board Of Regents Of The University Of Texas System Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
EP3774709A4 (en) * 2018-03-28 2021-12-22 Peloton Therapeutics, Inc. Methods of reducing inflammation of the digestive system with inhibitors of hif-2-alpha
US20210380536A1 (en) * 2018-10-17 2021-12-09 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
US20200361855A1 (en) 2019-04-18 2020-11-19 Nikang Therapeutics, Inc. Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US20220274914A1 (en) * 2019-07-22 2022-09-01 Nikang Therapeutics, Inc. Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors
AU2021256998A1 (en) * 2020-04-16 2022-10-20 Nikang Therapeutics, Inc. Hypoxia Inducible Factor-2(alpha) inhibitors and their use in the treatment of diseases

Also Published As

Publication number Publication date
CA3197932A1 (en) 2022-04-28
WO2022086822A1 (en) 2022-04-28
JP2023548666A (en) 2023-11-20
WO2022082329A1 (en) 2022-04-28
KR20230092936A (en) 2023-06-26
EP4229033A1 (en) 2023-08-23
TW202233569A (en) 2022-09-01
AU2021364337A1 (en) 2023-06-01
CN116507601A (en) 2023-07-28

Similar Documents

Publication Publication Date Title
Umemoto et al. Power-and structure-variable fluorinating agents. The N-fluoropyridinium salt system
IL301897A (en) PROCESSES OF PREPARING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDROSquire Patton Boggs (US) LLP - L.A.1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE
TWI778562B (en) Process for preparing a cot inhibitor compound
Marsais et al. A new convergent route to 1-substituted ellipticines
WO2022242278A1 (en) Preparation methods for upadacitinib and intermediate thereof
Casaschi et al. Palladium catalysed tandem cyclisation–anion capture. Part 7: Synthesis of derivatives of α-amino esters, nitrogen heterocycles and β-aryl/heteroaryl ethylamines via in situ generated vinylstannanes
Murphy et al. A radical based addition–elimination route for the preparation of indoles
US11634382B2 (en) Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile
Cheng et al. Convenient Synthesis of Terminal Alkynes from anti‐3‐Aryl‐2, 3‐dibromopropanoic Acids Using a K2CO3/DMSO System
KR20190134622A (en) Method for preparing 1- (4-methanesulfonyl-2-trifluoromethyl-benzyl) -2-methyl-1H-pyrrolo [2,3-b] pyridin-3-yl-acetic acid
Bera et al. Pd/C-catalyzed alkynylation of β-chloroacroleins
CN113105318B (en) Preparation method and application of 2, 2-difluorocyclobutane-1-carboxylic acid
CN114957097B (en) Preparation method of indoline compound
CN108003085A (en) A kind of synthetic method of pharmaceutical intermediate sweet-smelling formacyl indole derivatives
CN109422639B (en) Method for synthesizing 1, 2-dicarbonyl compound
CN116396209A (en) Alkyl perfluoroalkyl ketone compound and preparation method thereof
AU2023219866A1 (en) Compound, Preparation Method Therefor and Application of Compound in Preparation of Bicyclopyrone Intermediate
CN1950319B (en) Process for the production of cyclic diketones
CN115109060A (en) Method for selectively synthesizing quinoline-2-ketone by copper-catalyzed alpha-bromocarbonyl alkyne and maleimide serial cyclization
JP2001513104A (en) Method for preparing 4H-4-oxo-quinolidine-3-carboxylic acid derivative
JP2024505513A (en) Method for preparing 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid
JP2012521993A (en) Process for the production of fused tricyclic sulfonamides
JPH06220052A (en) Production of imide derivative
KR20070090937A (en) 2-(pyrazol-1-yl)pyridine derivative
EA044890B1 (en) PYRAZOLE COMPOUNDS AND THEIR PREPARATION